Source of Cell-Free Fetal DNA in Maternal Plasma
Cell-free fetal DNA detected in maternal plasma originates from placental trophoblast cells, not from the intervillous space or fetal circulation. 1
Origin and Cellular Source
The cell-free DNA (cfDNA) circulating in maternal blood is specifically derived from placental trophoblastic cells, comprising approximately 10-15% of total cfDNA in maternal plasma after 10 weeks of gestation. 1 This has been definitively established through studies of anembryonic pregnancies (pregnancies with placental tissue but no fetus), which demonstrate normal levels of cell-free fetal DNA despite the complete absence of a fetus—proving the trophoblast is the primary source. 2
Key Evidence Supporting Trophoblastic Origin
Anembryonic pregnancy studies show that cfDNA levels remain normal (median 148.3 GE/mL) even when no embryo is present, confirming the placenta as the source rather than fetal tissues. 2
Cytotrophoblastic layer specificity: Research using pregnancies with confined placental mosaicism (where the cytotrophoblast has different chromosomes than the fetus) demonstrates that cfDNA reflects the cytotrophoblastic genotype, not the fetal genotype. 3
Exclusion of fetal erythroblasts: Studies examining both fetal erythroblast counts and cfDNA concentrations in the same maternal samples found no correlation between these two parameters, ruling out transplacental passage of fetal blood cells as the source. 4
Clinical Implications of Placental Origin
Why This Matters for Testing
The placental origin of cfDNA explains several important clinical phenomena:
Confined placental mosaicism can cause false-positive results when the trophoblast carries chromosomal abnormalities not present in the fetus itself. 1
Vanishing twin syndrome leads to false-positive results because DNA from the demised twin's placenta persists in maternal circulation. 1
Test timing requirements: cfDNA becomes reliably detectable only after 10 weeks gestation when placental mass and trophoblastic turnover are sufficient to generate adequate fetal fraction (10-15% of total cfDNA). 1, 5
Common Pitfall to Avoid
Do not assume cfDNA results are definitively diagnostic of fetal genotype. Because the source is placental trophoblast rather than fetal tissue, discordance between placental and fetal chromosomes occurs in approximately 1-2% of cases due to confined placental mosaicism. 1, 3 This is why all positive cfDNA screening results require confirmatory diagnostic testing (amniocentesis or CVS) before making irreversible clinical decisions. 1
Mechanism of Release
Cell-free fetal DNA consists of small fragments (<200 base pairs) released into maternal circulation through apoptosis and turnover of placental trophoblastic cells. 1, 6 The DNA fragments are detectable from approximately 7 weeks gestation but reach clinically useful concentrations (≥10% fetal fraction) by 10 weeks. 5, 6
Factors Affecting cfDNA Levels
Maternal obesity significantly reduces fetal fraction, with test failure rates of 20% in women >250 lb and 50% in women >350 lb. 1, 7
Placental pathology (preeclampsia, preterm labor) increases cfDNA release without increasing fetal cell trafficking, further confirming the placental rather than fetal origin. 4
Gestational age <10 weeks results in insufficient fetal fraction for reliable testing. 5, 7